Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExoFlo for Medically Refractory Crohn's Disease
NCT05130983Phase 1Terminated
- Sponsor
- Direct Biologics
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bone marrow mesenchymal stem cell derived extracellular vesicles in Crohn's disease, sponsored by Direct Biologics. Primary endpoints: Safety of intravenous ExoFlo at 58 weeks and Feasibility of intravenous ExoFlo at 58 weeks. Started Jan 2023; status: terminated.
02
Drugs
bone marrow mesenchymal stem cell derived extracellular vesicles
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05130983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130983.